- Home
- ADEA vs SLS Comparison
ADEA vs SLS Comparison
Compare ADEA & SLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ADEA | SLS |
|---|---|---|
| Founded | 1990 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.6B | 2.1B |
| IPO Year | 2020 | 2007 |
Fundamental Metrics
Financial Performance| Metric | ADEA | SLS |
|---|---|---|
| Price | $20.99 | $9.48 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 4 | 2 |
| Target Price | ★ $43.00 | $32.50 |
| AVG Volume (30 Days) | 1.1M | ★ 6.2M |
| Earning Date | 11-02-2026 | 11-11-2026 |
| Dividend Yield | ★ 0.89% | N/A |
| EPS Growth | ★ 73.68 | 50.00 |
| EPS | ★ 0.35 | N/A |
| Revenue | ★ $443,386,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $8.42 | N/A |
| P/E Ratio | $63.91 | ★ N/A |
| Revenue Growth | ★ 17.91 | N/A |
| 52 Week Low | $11.61 | $1.39 |
| 52 Week High | $34.34 | $15.88 |
Technical Indicators
Market Signals| Indicator | ADEA | SLS |
|---|---|---|
| Relative Strength Index (RSI) | 37.44 | 37.41 |
| Support Level | $20.33 | $4.09 |
| Resistance Level | $26.18 | $9.51 |
| Average True Range (ATR) | 0.92 | 1.08 |
| MACD | 0.09 | -0.14 |
| Stochastic Oscillator | 18.91 | 4.85 |
Price Performance
Historical ComparisonAbout ADEA Adeia Inc.
Adeia Inc is a consumer and entertainment product/solutions licensing company. It's the only operating segment, being Intellectual Property (IP) Licensing. In the IP segment, the company licenses innovations to companies in the broader entertainment industry and those developing new technologies that will help drive this industry forward. It includes Pay-TV, Consumer Electronics, Connected Car, and Media Platform.
About SLS SELLAS Life Sciences Group Inc.
SELLAS Life Sciences Group Inc is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. The company's product candidates currently include galinpepimut-S, or GPS, a peptide immunotherapy directed against the Wilms tumor 1, or WT1, antigen, and GFH009, a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor.